#George Claessen

[thatsbutterbaby]

George Claessen (1909-1999) - Le Sourie, 1966.   Oil on canvas/  (91 x 70.8 cm.

#George Claessen #Le Sourie

[theatricalowl]

DER VAMPYR Marschner – Staatsoper Hannover

CAST 

Sir Humphrey, Laird van Davenaut: Shavleg Armasi 

Malwina: Mercedes Arcuri 

Edgar Aubry: Norman Reinhardt 

Lord Ruthven: Michael Kupfer-Radecky 

Sir Berkley: Daniel Eggert 

Janthe: Petra Radulovic 

George Dibdin: Philipp Kapeller 

Emmy: Nikki Treurniet 

James Gadshill: Pawel Brozek 

Richard Scrop: Peter O'Reilly 

Robert Green: Darwin Prakash / Gagik Vardanyan 

Toms Blunt: Markus Suihkonen 

Suse: Weronika Rabek 

Astarte / Vampyrmeisterin: Oana Solomon 

Vampyr/Lord Byron: Benny Claessens 

Ahasver: Jonas Grundner-Culemann 

Chorus: Chor der Staatsoper Hannover 

Orchestra: Niedersächsisches Staatsorchester Hannover

#der vampyr #opera #opera tag #heinrich marschner #video

[mixedmediasintlucas]

Mixed Media invited at EMAF, Osnabrück, Germany

Haus der Jugend, Grosse Gildewart 6 - 9, Osnabrück, Germany

25 - 27 April     10:00 – 22:00

Full program: https://www.emaf.de/files/emaf_programm-2019_en.pdf

Following a very successful launch in the Theaterpassage last year, the INIT Experience festival section as part of the EMAF festival is to be continued at Haus der Jugend. Classes and subject groups from various higher education institutions and academies use this experimental exhibition context to showcase their work. The Mixed Media Studio (LUCA School of Arts, Ghent), coordinated by Roel Kerkhofs presents what is referred to as exhibition performances, which can be set up in the Main Hall and dismantled again within the space of an hour. Mixed Media Studio advances in the festival the sensory possibilities of artists talks, performative exhibitions, artistic clubbing and other art happenings…

Works by Kiki Abels, Stan Auwers, Sarah Buniowski, Jan Claerbout, Elia Claessen, Renske Cocquyt, Sjef Cocriamont, Ewout De Cat, Ben De Graeve, Anna De Sutter, Janne Gistelinck, Catarina Gonçalves, Oonagh Haines, Finley Hunt, Sjeng Kessels, Sun Kim, Mose Lein, Thuy Le Thi Thu,  Nello Margodt, Siebert Mispelon, Mozes Mosuse, Roos Nieboer, Eleni Papadopoulou, Matteo Patelli, Tasha Joan Paul, Zeno Peeters, Nyall Smith, Loeka Stoop, Fela Susant, Charlotte Symoens, Nina-joy Thielemans, Elvira Tjon, Emiel Vandekerckhove, Magnus Vandenbergh, Ryan Vander Elst, Oscar Van geertruyden and Tobin Verdonck

Participating schools at INIT (EMAF):

University of the Arts Bremen (G), Filmic Spaces and Conceptual Photography class (Professor Rosa Barba)

LUCA School of Arts Ghent (B), Mixed Media Studio (Professor Roel Kerkhofs)

AKI Academy of Art and Design in Enschede (NL), Fine Art All Space & Sculpture (Prof. Paul Jansen Klomb & Prof. Pieter Baan Muller)

KHM (G), exMedia subject group (Professors Anke Eckardt, hans w koch, Franziska Windisch, Georg Trogemann, Isabel Herguera, Zilvinas Lilas)

[mariebenz]

Even with Controlled LDL-Cholesterol, PCI Stent Patients Have Residual Inflammatory Risk

MedicalResearch.com Interview with:

Dr. Dangas Dr. George Dangas MD PhD Professor of Medicine, Cardiology Mount Sinai Health System MedicalResearch.com: What is the background for this study? Response: Widespread use of statins targeted to decrease levels of low density lipoprotein cholesterol (LDL-C) below 70mg/dL are recommended by guidelines. However, residual cholesterol risk may only be one part of the residual risk equation. Indeed, Biological inflammation has long been known as a pathophysiological mechanism of atherosclerosis and the recent CANTOS trial opened new therapeutic perspective by demonstrating that inflammation modulation via selective interleukin-1β inhibition could result in improved diagnosis in patients with coronary artery disease. However, the prevalence and impact of a residual inflammatory biological syndrome in patients with controlled cholesterol risk is unclear. MedicalResearch.com: What are the main findings? Response: In the study we demonstrated that in patients undergoing PCI with controlled LDL-C at baseline, risk of adverse events remained high, despite the optimized medical treatment. The presence of persistent residual inflammatory risk (defined as hsCRP >2 mg/L in ≥2 serial measurement with at least 4 weeks delay) was present in a third of patients with controlled LDL-C at baseline and was independently associated with adverse events.  MedicalResearch.com: What should readers take away from your report? Response: The need for thorough control of the cholesterol risk in patients with coronary artery disease is now well implemented in the minds and practice of physician. Our study shows the importance of the presence of persistent inflammatory risk overtime. MedicalResearch.com: What recommendations do you have for future research as a result of this work? Response: Our study warrants the realization of prospective therapeutic trials evaluating the impact of inflammation modulation, particularly, via selective inflammatory inhibition, in patients with coronary artery disease, with optimized medical treatment and controlled cholesterol risk. Disclosures: This study was performed in the Center for Interventional Cardiovascular research and clinical trial of the Zena and Michael A. Weiner Cardiovascular Institute of the Icahn School of Medecine. Full author disclosures at the relevant publication. Dr. Dangas reports nothing relevant to the subject of this interview.  Citation: Impact of Residual Inflammatory Risk in Patients With Low LDL-Cholesterol Undergoing Percutaneous Coronary Intervention: Insight From a Large Single-Center Registry Paul Guedeney, Bimmer Claessen, Deborah Kalkman, Melissa Aquino, Sabato Sorrentino, Moritz Blum, Gennaro Giustino, Serdar Farhan, BirgitVogel, Samantha Sartori, Gilles Montalescot, Joseph Sweeny, JasonKovacic, Nitin Barman, George Dangas, Annapoorna Kini, Usman Baber, Samin Sharma, Roxana Mehran Journal of the American College of Cardiology Mar 2019, 73 (9 Supplement 1) 11; DOI: 10.1016/S0735-1097(19)30620-5               The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.   Read the full article

#ACC19 #heartdisease #IcahnMountSinai #LDL #lipids #MountSinaiNYC

[thatsbutterbaby]

George Claessen (1909-1999) - Abstract, 1957.   Oil on canvas/ 61.5 x 51cm.  

#George Claessen #Abstract

[thatsbutterbaby]

George Claessen (1909-1999) - Abstract IV.  Oil on canvas /  52 x 33 cm.  

#George Claessen #Abstract IV

[thatsbutterbaby]

George Claessen (1909-1999) - Abstract VI.  Oil on canvas / 44.5 x 59.5 cm. 

#George Claessen #Abstract VI